title: [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].
abstract: OBJECTIVE
  Functional status and quality of life outcomes in Latin American outpatients with schizophrenia were compared after 12 months of monotherapy treatment with olanzapine, risperidone or typical antipsychotics.
  
  
  METHODS
  Both outcomes were assessed as part of a prospective, large (N= 7658), international (27 countries), observational study.
  
  
  RESULTS
  from the Latin American subpopulation (N= 2671; 11 countries) are presented. Compared to typical antipsychotics, olanzapine and risperidone were associated with significantly (p < 0.05) greater odds of employment and social activity, and significantly greater improvements in quality of life. Olanzapine was also associated with significantly greater odds of living independently, compared to typical antipsychotics.
  
  
  CONCLUSIONS
  This study indicates that functional status and quality of life outcomes are likely to be more favorable when Latin American outpatients with schizophrenia are treated with olanzapine or risperidone monotherapy, rather than typical antipsychotics.
authors.affiliation: jrovner@lilly.com
authors.forename: Jorge
authors.initials: J
authors.lastname: Rovner
authors.forename: Sheila
authors.initials: S
authors.lastname: Assunção
authors.forename: Pedro
authors.initials: P
authors.lastname: Gargoloff
authors.forename: Hernan Silva
authors.initials: HS
authors.lastname: Ibarra
authors.forename: Jaime Aguilar
authors.initials: JA
authors.lastname: Gasca
authors.forename: Erick Landa
authors.initials: EL
authors.lastname: Fournais
authors.forename: Pablo
authors.initials: P
authors.lastname: Adan
authors.forename: Nestor J
authors.initials: NJ
authors.lastname: Andrades
authors.forename: Yulia
authors.initials: Y
authors.lastname: Dyachkova
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D003024:Clozapine / Q000627:therapeutic use*; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D000077152:Olanzapine; D011788:Quality of Life; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine